βeta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trial
Authors:
- 20 January 2023
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 258, 168-176
Abstract
No abstract availableKeywords
Funding Information
- Ministère des Affaires Sociales et de la Santé
This publication has 27 references indexed in Scilit:
- Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarctionHeart, 2015
- β-Blockers and Cardiovascular Events in Patients With and Without Myocardial InfarctionCirculation: Cardiovascular Quality and Outcomes, 2014
- Clinical Outcomes with β-Blockers for Myocardial Infarction: A Meta-analysis of Randomized TrialsThe American Journal of Medicine, 2014
- β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery DiseaseJAMA, 2012
- 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort studyBMJ, 2012
- Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countriesEuropean Heart Journal, 2009
- EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countriesEuropean Journal of Preventive Cardiology, 2009
- Risk factors for myocardial infarction in women and men: insights from the INTERHEART studyEuropean Heart Journal, 2008
- Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarctionEuropean Heart Journal, 2006
- Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trialThe Lancet, 2005